Data from January 1999 to November 2001; hemodialysis patients who received at least 10 doses of vitamin D therapy
The paricalcitol group had a lower risk of first all-cause hospitalization (14% less, ), fewer hospitalizations per year (0.642 fewer, ) and fewer hospital days per year (6.84 fewer, ) versus calcitriol
A historical cohort study to compare the 36-month survival rate among dialysis patients receiving treatment with paricalcitol (29,021 patients) versus calcitriol (38,378 patients).
The mortality rate among patients receiving paricalcitol was 0.180 per person-year versus 0.223 per person-year among those receiving calcitriol (). The difference in survival was significant at 12 months and increased with time. In the adjusted analysis, the mortality rate was 16 percent lower (95% CI, 10 to 21 percent) among paricalcitol-treated patients than among calcitriol-treated patients. At 12 months, calcium and phosphorus levels had increased by 6.7 and 11.9 percent, respectively, in the paricalcitol group, as compared with 8.2 and 13.9 percent, respectively, in the calcitriol group ().
31 patients (calcitriol: ; paricalcitol: ; doxercalciferol: ) in the years 1999–2004. Median follow-up was 37 weeks.
Mortality rates (deaths/100 patient-years) were identical in patients treated with doxercalciferol (15.4, 95% CI 13.6–17.1) and paricalcitol (15.3, 13.6–16.9) and higher in patients on calcitriol (19.6, 18.2–21.1) (). Overall, mortality was higher for patients who did not receive vitamin D versus those who did.
